Creative Diagnostics Announces SARS-CoV-2 Antibody Pairs for Rapid COVID-19 Antigen Assays
Creative Diagnostics announces the launch of the SARS-CoV-2 antibody pairs against the nucleoprotein antigens of SARS-CoV-2.
- (1888PressRelease) January 22, 2021 - As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics announces further expansion of its SARS-CoV-2 related product portfolio with the launch of the SARS-CoV-2 antibody pairs against the nucleoprotein antigens of SARS-CoV-2. These antibodies were screened from thousands of clones and selected for their high sensitivity and specificity in lateral flow applications.
Creative Diagnostics now provides a variety of antigens and antibodies of SARS-CoV-2, including SARS-CoV-2 mutant proteins, biotinylated proteins, SARS-CoV-2 antibody pairs, neutralizing antibodies and so on. These antigens and antibodies can be used for scientific research, detection of SARS-CoV-2 and specific antibodies. All of Creative Diagnostics products are produced using a standardized production process to ensure the highest quality.
These newly released SARS-CoV-2 antibodies are validated for rapid antigen assays and can be used in commercially launched assays all over the world, such as the capture antibody, Creative Diagnostics' Anti-SARS-CoV-2 Nucleoprotein monoclonal antibody (CABT-MMB1), which can be used for ELISA and LFIA. It is noted that this product is for research and laboratory use only and is not intended for diagnostic, therapeutic, drug, household or other uses.
"Considering many scientists are still pursuing their academic research on SARS-CoV-2 to fight against COVID-19, Creative Diagnostics will continue to focus on the mission to serve life scientists and makes efforts to help enhance their research capabilities in identifying the spike protein. Creative Diagnostics is proud to have developed and delivered these SARS-CoV-2 antibody pairs, and these new products are the extension of our antibody portfolio. With combination of our immunoassay expertise, we'll expand our manufacturing capability to assist the research community to combat this pandemic." said Prof. Mike Knuth, M.D., the chief scientific officer of R&D department of Creative Diagnostics.
"We've expanded our SARS-CoV-2 antibody product portfolio for COVID-19 studies, and our team has tested hundreds of anti-nucleocapsid antibody pairs to recommend researchers the best pair for further development of an LFA for SARS-CoV-2 antigen. We also offer SARS-CoV-2 antigen extraction buffer tubes that can be used as packing supplies for SARS-CoV-2 antigen extraction." said Dr. Jessica Waldorf, chief scientific officer of R&D department of Creative Diagnostics.
If you want to know more information about SARS-CoV-2 related testing products or other coronavirus research materials, please contact Creative Diagnostics directly.
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. It aims to provide a trusted source for all researchers' assay development and manufacturing needs.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam